New two-year preclinical program for EHMT1 gene replacement

A new research project is attempting to answer a fundamental question about Kleefstra syndrome: can a functional copy of EHMT1 be delivered in a controlled and acceptably safe manner to the appropriate cells of the central nervous system? IDefine and UT Southwestern Medical Center announced on June 3, 2026, a two-year collaboration to investigate this approach.

It is important for families to be clear from the outset about what exactly was announced. It is preclinical research program, meaning for laboratory and potentially research in models prior to any study in humans. No participants, treatment administration, or clinical trial were announced. There are no data yet showing benefit for people with Kleefstra syndrome, and the research strategy is not available as a treatment.

What the collaboration will investigate

IDefine committed approximately $310,000 for the two-year project, which is led by Steven Gray, PhD, at UT Southwestern. According to the announcement, the program is expected to continue through April 2028. Its goal is to evaluate whether an EHMT1 gene replacement strategy can be delivered to the central nervous system, with a particular focus on controlling the level of gene expression.

Kleefstra syndrome type 1 is usually caused by deficiency of a functional copy of EHMT1out of the two copies of the gene, one does not function adequately, with the result that the overall activity of EHMT1 is not sufficient for typical development and function. Gene replacement seeks, at the level of research principle, to add functional genetic material so that a sufficient amount of the corresponding protein is produced in the relevant cells.

This direct connection to the underlying genetic cause makes the approach scientifically interesting, but it does not automatically make it effective or safe. EHMT1 is an epigenetic regulator: it helps control the use of many other genes. Therefore, simply producing more EHMT1 is not enough. The amount, the cells in which it will be expressed, the extent of distribution in the brain, and the duration of expression can be critical parameters.

Why dose control is a central issue

In EHMT1 deficiency, very low functional activity is linked to the disease. However, the uncontrolled or excessive expression of an epigenetic regulator could also create problems. This is why controlling the level of gene expression is not a secondary technical detail, but a central question of feasibility and safety.

The announcement refers to next-generation delivery technology targeting the central nervous system. It does not publicly specify a particular vector type, serotype, dose, route of administration, animal model, or human-ready product. Targeted delivery to the central nervous system is a research goal and not a guarantee that the genetic material will reach all relevant cells. The program must first evaluate whether the approach can be engineered and administered in a way that justifies further development.